Six-month results of a repositionable and retrievable pericardial valve for transcatheter aortic valve replacement: The Direct Flow Medical aortic valve

被引:31
作者
Treede, Hendrik [1 ,2 ]
Tuebler, Thilo [3 ]
Reichenspurner, Hermann [1 ,2 ]
Grube, Eberhard [4 ]
Pascotto, Andrea [3 ]
Franzen, Olaf [1 ,2 ]
Mueller, Ralf [4 ]
Low, Reginald [5 ]
Bolling, Steven F. [6 ]
Meinertz, Thomas [1 ,2 ]
Schofer, Joachim [3 ]
机构
[1] Univ Heart Ctr Hamburg, Dept Cardiovasc Surg, D-20246 Hamburg, Germany
[2] Univ Heart Ctr Hamburg, Dept Cardiol, D-20246 Hamburg, Germany
[3] Univ Hamburg, Med Care Ctr Prof Mathey, Ctr Cardiovasc, Hamburg, Germany
[4] HELIOS Heart Ctr Siegburg, Dept Cardiol Angiol, Siegburg, Germany
[5] Univ Calif Davis, Med Ctr, Div Cardiovasc Med, Sacramento, CA 95817 USA
[6] Univ Michigan, Ctr Cardiovasc, Ann Arbor, MI 48109 USA
关键词
HIGH-RISK PATIENTS; PROSTHESIS; STENOSIS; DISEASE; SYSTEM;
D O I
10.1016/j.jtcvs.2010.01.017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Transcatheter aortic valve implantation is considered an alternative for patients at high risk for conventional surgery. The Direct Flow Medical aortic valve (Direct Flow Medical, Inc, Santa Rosa, Calif) is a nonmetallic tissue valve prosthesis intended to treat patients with severe aortic stenosis at high risk for surgery. Methods: Thirty-one patients at high surgical risk were enrolled in the trial (logistic EuroSCORE 28% +/- 7%, Society of Thoracic Surgeons score 23% +/- 9%). Twenty-two patients underwent successful retrograde transcatheter aortic valve implantation, and 9 patients did not undergo implantation owing to excessive calcifications or access issues. Mean preinterventional gradient and effective orifice area were 49 +/- 14 mm Hg and 0.54 +/- 0.16 cm(2), respectively, and 71% of patients were in New York Heart Association functional class III. Results: Mean postprocedural gradient was 14.9 +/- 5.5 mm Hg with an effective orifice area of 1.4 +/- 0.31 cm(2). Two patients were converted to surgery and 2 patients died after implantation: 1 of myocardial infarction and 1 of congestive heart failure. One patient had a stroke 2 days after the procedure and 3 patients required a pacemaker. At 6 months the mean aortic valve gradient and effective orifice area were 19.8 mm Hg and 1.30 cm(2), respectively. The majority of patients had no paravalvular leak (58%) and 42% had grade 1/4 paravalvular leak; 69% were in New York Heart Association functional class I and 25% were in class II. The 3- and 6-month survivals were 87.1% and 80.6%, respectively (4/6 deaths in 31 patients). Conclusions: Transcatheter aortic valve implantation using the study valve appears safe and results are promising at 6 months. Severe leaflet and left ventricular outflow tract calcification affects procedural outcome; therefore, careful patient selection is crucial. (J Thorac Cardiovasc Surg 2010; 140: 897-903)
引用
收藏
页码:897 / 903
页数:7
相关论文
共 12 条
  • [1] Bolling Steven F, 2008, EuroIntervention, V4, P148, DOI 10.4244/EIJV4I1A23
  • [2] Percutaneous aortic valve replacement for severe aortic stenosis in high-rick patients using the second- and current third-generation self-expanding CoreValve prosthesis - Device success and 30-day clinical outcome
    Grube, Eberhard
    Schuler, Gerhard
    Buellesfeld, Lutz
    Gerckens, Ulrich
    Linke, Axel
    Wenaweser, Peter
    Sauren, Barthel
    Mohr, Friedrich-Wilhelm
    Walther, Thomas
    Zickmann, Bernfried
    Iversen, Stein
    Felderhoff, Thomas
    Cartier, Raymond
    Bonan, Raoul
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (01) : 69 - 76
  • [3] Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease - The Siegburg First-in-Man Study
    Grube, Eberhard
    Laborde, Jean C.
    Gerckens, Ulrich
    Felderhoff, Thomas
    Sauren, Barthel
    Buellesfeld, Lutz
    Mueller, Ralf
    Menichelli, Maurizio
    Schmidt, Thomas
    Zickmann, Bernfried
    Iversen, Stein
    Stone, Gregg W.
    [J]. CIRCULATION, 2006, 114 (15) : 1616 - 1624
  • [4] A prospective survey of patients with valvular heart disease in Europe:: The Euro Heart Survey on Valvular Heart Disease
    Iung, B
    Baron, G
    Butchart, EG
    Delahaye, F
    Gohlke-Bärwolf, C
    Levang, OW
    Tornos, P
    Vanoverschelde, JL
    Vermeer, F
    Boersma, E
    Ravaud, P
    Vahanian, A
    [J]. EUROPEAN HEART JOURNAL, 2003, 24 (13) : 1231 - 1243
  • [5] LABORDE JC, 2008, TRANSC CARD THER OCT
  • [6] Low Reginald I, 2008, EuroIntervention, V4, P256, DOI 10.4244/EIJV4I2A45
  • [7] European system for cardiac operative risk evaluation (EuroSCORE)
    Nashef, SAM
    Rogues, F
    Michel, P
    Gauducheau, E
    Lemeshow, S
    Salamon, R
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1999, 16 (01) : 9 - 13
  • [8] Expansion of mesenchymal stem cells using a microcarrier-based cultivation system: growth and metabolism
    Schop, D.
    Janssen, F. W.
    Borgart, E.
    de Bruijn, J. D.
    van Dijkhuizen-Radersma, R.
    [J]. JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE, 2008, 2 (2-3) : 126 - 135
  • [9] THOMAS M, 2009, EUROPCR MAY 20 BARC
  • [10] VAHANIAN A, 2008, EUROINTERVENTION, V2, P193